Science Advances: PARP1 inhibitors are expected to be an effective treatment strategy for PDAC

Pancreatic cancer is known as the "king of cancer" and pancreatic catheter cancer (PDAC) is the most common type.
the incidence of PDAC hidden, rapid development, accounting for about 90% of the incidence of pancreatic cancer.
the difficulty of treating PDAC is usually associated with fibrosis of the tumor, which forms connective tissue throughout the pancreas, fighting drugs and the immune system to help cancer cells grow.
a recent study published in the journal Science Advances, scientists found that DNA mutations appear to make many pancreatic tumors appear to be susceptible to PARP inhibitors, which are concentrated in the MYBBP1A gene.
in pancreatic cancer cells and mouse models, researchers have found that DNA loss is common in pancreatic cancer, which in turn increases the sensitivity of pancreatic tumors to drugs.
researchers used CRISPR-Cas9 technology to induce the insertion or absence of the MYBBP1A gene and to test the importance of MYBBP1A in PDAC cells by using sgRNA from the ROSA allegase gene.
results showed that pancreatic cancer cells grew three times less after 15 days of targeting myBBP1A sgRNA transductive cells than non-targeted sgRNAs.
a lengthy examination of MYBBP1A cells by immunofluorescence and immune imprinting, and it was found that MYBBP1A continued to express after several weeks of cell culture, possibly due to the selective exoded expression of escaped cells.
, this suggests that cell growth is due to the loss of MYBBP1A cells and is not affected by the nonse specificity of cell division.
study of the interaction between PARAP1 inhibitors destroying MYBBP1A and polykernels further found that the use of genetic engineering techniques to inflamm the remaining copies of MYBBP1A effectively prevented the progression of PDAC cell cancer.
same time, the researchers also found that the MYBBP1A protein works on the nucleal DNA of cells to promote the activity of growth genes and interacts closely with proteins called PARP1 proteins.
this means that anticancer drugs for PARP1 inhibitors may prevent the development of PDAC.
researchers say they hope to be able to conduct clinical trials of PARP1 inhibitors in pancreatic cancer patients in the future to speed up the application of PARP1 inhibitor strategies and give patients good news.
。